AB Science SA, a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced today recruitment of the first patient in the phase 3 study of masitinib in primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis.
This is an international, multicenter, randomized, double-blind, placebo-controlled, phase 3 study. Its objective is to compare the efficacy and safety of masitinib at 6 mg/kg/day with placebo in the treatment of patients with primary progressive multiple sclerosis or relapse free secondary progressive multiple sclerosis. This study will enroll approximately 450 patients, across 60 centers around the world, randomized with a ratio of 2:1 between the masitinib and placebo groups. The primary response evaluation will be the proportion of patients to achieve an improvement of at least 100% in their symptoms, as measured by the Multiple Sclerosis Functional Composite (MSFC) score, after 96 weeks of treatment.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/3226
